CoheSIL to enter silicone breast implant trial:
This article was originally published in Clinica
Executive Summary
McGhan Medical, of Santa Barbara, California, is to begin a multicentre US trial of its new silicone breast implant, CoheSIL. The implant is made of cohesive silicone gel and is encased in a silicone shell that is more durable than previous models. The shell is also designed to hold its shape better than the current saline implants. Around half of the 940 patients in the trial will undergo augmentation and the remainder reconstruction or revision surgery. Safety concerns in the 1980s prompted litigation regarding silicone breast implants, and eventually led to their withdrawal for use in routine breast augmentation in the US.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.